HOME >> MEDICINE >> NEWS
ENDEAVOR III Trial reports key findings on new-generation stent

(May 10, 2007ORLANDO, FL) -- New data reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 912, 2007, in Orlando, FL, will offer clues to the fate of a new-generation drug-eluting stent that is vying for a place in the treatment of coronary artery disease.

The Endeavor III trial randomly assigned 436 patients treated at 30 medical centers in the United States to treatment with the investigational Endeavor stent (Medtronic, Minneapolis) or the Cypher stent (Cordis Johnson & Johnson, Miami Lakes, FL). The Endeavor stent is coated with zotarolimus, a medication that, like the Cyphers sirolimus coating, reduces renarrowing of the artery by preventing the growth of scar tissue inside the stent.

Initial data showed that procedural success was higher with the new Endeavor stent, which is more flexible and is considered easier to implant than the Cypher stent. However, at 8 months, the Endeavor stent fell short in angiographic studies, showing significantly greater scar tissue growth, or late loss, in the inner diameter of the artery as compared to the Cypher stent. At 12 months, clinical outcomes were equivalent with the two stents: The combined rates of death, heart attack, and repeat procedures were 8.2 percent in both groups of patients.

At the Orlando SCAI meeting, Martin Leon, M.D., FSCAI, a professor of medicine and associate director of the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York City, will report 2-year clinical outcomes from the Endeavor III trial.

"Long-term follow-up will further clarify not only safety with the zotarolimus-eluting stent but also whether early angiographic disparities translate into differences in late clinical restenosis," he said.

The Endeavor III trial is 1 of 5 studies gathering the data necessary for market approval of the new stent by the Food and Drug Administra
'"/>

Contact: Kathy Boyd David
kbdavid@scai.org
717-422-1181
Society for Cardiovascular Angiography and Interventions
10-May-2007


Page: 1 2

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. NIH names Clinical Trial Units for the Microbicide Trials Network
5. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
6. The Public Library of Science launches the new open access journal PLoS Clinical Trials
7. Trial shows vaccine against cervical cancer provides long-term protection
8. Trial shows malaria vaccine could protect young children from disease for 18 months
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... today announced the 10th Anniversary of Blood Cancer Awareness Month (BCAM) and its ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... solution for chiropractors, announced today the launch of its integrated, HIPAA compliant, telehealth ... running their virtual practice in under 90 seconds. , According to the ...
(Date:8/31/2020)... MAUI, Hawaii (PRWEB) , ... August 31, 2020 , ... A Cure for Covid-19 “PTS” ... most people on the planet are in a state of panic, experiencing deep anxiety, immense ... , Right now, a solution is timely when most people on the planet are experiencing ...
(Date:8/29/2020)... ... August 29, 2020 , ... When professor and author Randy Pausch ... than most people would. Rather than become melancholic, however, he put together a final ... one’s dreams. Randy Pausch took a negative situation and turned it into something that ...
(Date:8/28/2020)... DOWNERS GROVE, Ill. (PRWEB) , ... August 28, ... ... to COVID-19, The Nourished Group set out to continue helping the ... , attendees can discover new gluten-free products, get coupons, enter giveaways, chat with ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... August 27, 2020 , ... Bridge To A Cure Foundation announces the ... adult and pediatric neuro-oncologist who serves on the Board of Directors at The Preston ... University Medical School. , Internationally recognized, Dr. Friedman is a widely published author of ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... expands its technology footprint with the addition of Novocyte Quanteon™ as a ... biomarker solutions, complemented with traditional ligand-binding assays and study management services, clients ...
(Date:8/26/2020)... ... August 26, 2020 , ... Crossroads Hospice & Palliative ... and CPCO to her name. , That’s thanks to her completion of two ... Certified Professional Compliance Officer (CPCO.) , The CHC is designed to mitigate compliance-related ...
Breaking Medicine Technology:
Cached News: